TABLE 3.
OVA dose (mg) | % Contribution of blood plasma transudate to:
|
||
---|---|---|---|
Anti-OVA IgA titersb in:
|
Fluid vol sampled from jejunal surfacec | ||
Jejunal secretions | Feces | ||
0.2 | 1.78 ± 3.55 | 0.84 ± 1.80 | 0.72 ± 0.74 |
2 | 1.35 ± 1.25 | 0.86 ± 0.40 | 0.59 ± 0.85 |
20 | 5.60 ± 9.53 | 0.89 ± 1.18 | 2.73 ± 3.10 |
All doses | 2.91 ± 5.51 | 0.86 ± 1.10 | 1.35 ± 1.95 |
Individual anti-OVA endpoint titers from three randomly selected animals of each OVA immunization group or all nine animals together were used to calculate the given data. No significant between-group differences could be detected for either sample or calculation mode (one-way ANOVA, P ≥ 0.364).
Percentage of blood-borne specific IgA in the specific IgA content of the mucosal sample (calculated using equation 1).
Percentage of the fluid volume sampled being blood plasma transudate (calculated using equation 2).